Skip to main content Accessibility help

We use cookies to distinguish you from other users and to provide you with a better experience on our websites. Close this message to accept cookies or find out how to manage your cookie settings.

Close cookie message
×
Hostname: page-component-84b7d79bbc-5lx2p Total loading time: 0 Render date: 2024-07-30T07:34:30.454Z Has data issue: false hasContentIssue false

Chapter 12 - Giant Cell Arteritis

from Section 2 - Inflammatory Conditions

Published online by Cambridge University Press:  15 June 2018

By
Sachin Kedar  and
James J. Corbett
Edited by
Louis Caplan  and
José Biller
Louis Caplan
Affiliation:
Beth Israel-Deaconess Medical Center, Boston
José Biller
Affiliation:
Loyola University Stritch School of Medicine, Chicago
Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Chapter
Information
Uncommon Causes of Stroke , pp. 87 - 95
Publisher: Cambridge University Press
Print publication year: 2018

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

Achkar, AA, Lie, JT, Hunder, GG, O’Fallon, WM, Gabriel, SE. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med 1994; 120: 987–92.Google Scholar
Alba, MA, Garcia-Martinez, A, Prieto-Gonzalez, S, et al. Relapses in patients with giant cell arteritis: Prevalence, characteristics, and associated clinical findings in a longitudinally followed cohort of 106 patients. Medicine (Baltimore) 2014; 93: 194–201.CrossRefGoogle Scholar
Almarzouqi, SJ, Morgan, ML, Lee, AG. Treatment of giant cell arteritis. Curr Opin Ophthalmol 2015; 26: 469–75.CrossRefGoogle ScholarPubMed
Amiri, N, De Vera, M, Choi, HK, Sayre, EC, Avina-Zubieta, JA. Increased risk of cardiovascular disease in giant cell arteritis: A general population-based study. Rheumatology (Oxford) 2016; 55: 33–40.CrossRefGoogle ScholarPubMed
Andersson, R, Malmvall, BE, Bengtsson, BA. Acute phase reactants in the initial phase of giant cell arteritis. Acta Med Scand 1986; 220: 365–7.CrossRefGoogle ScholarPubMed
Ball, EL, Walsh, SR, Tang, TY, Gohil, R, Clarke, JM. Role of ultrasonography in the diagnosis of temporal arteritis. Br J Surg 2010; 97: 1765–71.CrossRefGoogle ScholarPubMed
Baslund, B, Helleberg, M, Faurschou, M, Obel, N. Mortality in patients with giant cell arteritis. Rheumatology (Oxford) 2015; 54: 139–43.Google Scholar
Berti, A, Campochiaro, C, Cavalli, G, et al. Giant cell arteritis restricted to the limb arteries: An overlooked clinical entity. Autoimmun Rev 2015; 14: 352–7.Google Scholar
Carmona, FD, Mackie, SL, Martin, JE, et al. A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. Am J Hum Genet 2015; 96: 565–80.Google Scholar
Caselli, RJ, Hunder, GG, Whisnant, JP. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 1988; 38: 352–9.Google ScholarPubMed
Cavazza, A, Muratore, F, Boiardi, L, Restuccia, G, Pipitone, N, Pazzola, G, et al. Inflamed temporal artery: histologic findings in 354 biopsies, with clinical correlations. Am J Surg Pathol 2014; 38: 1360–70.Google Scholar
Caylor, TL, Perkins, A. Recognition and management of polymyalgia rheumatica and giant cell arteritis. Am Fam Physician 2013; 88: 676–84.Google ScholarPubMed
Chandran, AK, Udayakumar, PD, Crowson, CS, Warrington, KJ, Matteson, EL. The incidence of giant cell arteritis in Olmsted County, Minnesota, over a 60-year period 1950–2009. Scand J Rheumatol 2015; 44: 215–8.Google Scholar
Cid, MC, Font, C, Oristrell, J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum 1998; 41: 26–32.3.0.CO;2-0>CrossRefGoogle ScholarPubMed
Crowson, CS, Matteson, EL, Myasoedova, E, et al. The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011; 63: 633–9.Google Scholar
Danesh-Meyer, H, Savino, PJ, Gamble, GG. Poor prognosis of visual outcome after visual loss from giant cell arteritis. Ophthalmology 2005; 112: 1098–103.Google ScholarPubMed
Dasgupta, B, Borg, FA, Hassan, N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology (Oxford) 2010; 49: 1594–7.Google Scholar
Davies, CG, May, DJ. The role of temporal artery biopsies in giant cell arteritis. Ann R Coll Surg Engl 2011; 93: 4–5.Google Scholar
Dejaco, C, Singh, YP, Perel, P, et al. Current evidence for therapeutic interventions and prognostic factors in polymyalgia rheumatica: A systematic literature review informing the 2015 European League Against Rheumatism/American College of Rheumatology recommendations for the management of polymyalgia rheumatica. Ann Rheum Dis 2015; 74: 1808–17.Google Scholar
Gilden, D, White, T, Khmeleva, N, et al. Prevalence and distribution of VZV in temporal arteries of patients with giant cell arteritis. Neurology 2015; 84: 1948–55.Google Scholar
Gonzalez‐Gay, MA, Vazquez‐Rodriguez, TR, Lopez‐Diaz, MJ, et al. Epidemiology of giant cell arteritis and polymyalgia rheumatica. Arthritis Care Res 2009; 61: 1454–61.Google Scholar
Gonzalez-Gay, MA, Vazquez-Rodriguez, TR, Gomez-Acebo, I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine (Baltimore) 2009; 88: 227–35.Google Scholar
Hayreh, SS. Posterior ischaemic optic neuropathy: Clinical features, pathogenesis, and management. Eye (Lond) 2004; 18: 1188–206.Google Scholar
Hayreh, SS, Zimmerman, MB. Amaurosis fugax in ocular vascular occlusive disorders: Prevalence and pathogeneses. Retina 2014; 34: 115–22.Google Scholar
Hayreh, SS, Zimmerman, B. Visual deterioration in giant cell arteritis patients while on high doses of corticosteroid therapy. Ophthalmology 2003; 110: 1204–15.CrossRefGoogle ScholarPubMed
Hayreh, SS, Zimmerman, B, Kardon, RH. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 2002; 80: 355–67.CrossRefGoogle ScholarPubMed
Hayreh, SS, Podhajsky, PA, Zimmerman, B. Ocular manifestations of giant cell arteritis. Am J Ophthalmol 1998a; 125: 509–20.Google ScholarPubMed
Hayreh, SS, Podhajsky, PA, Zimmerman, B. Occult giant cell arteritis: Ocular manifestations. Am J Ophthalmol 1998b; 125: 521–6.Google Scholar
Hayreh, SS, Podhajsky, PA, Raman, R, Zimmerman, B. Giant cell arteritis: Validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997; 123: 285–96.Google Scholar
Horton, B, Magath, T, Brown, G. An undescribed form of arteritis of the temporal vessels. Mayo Clin Proc 1932; 7: 700–1.Google Scholar
Hunder, GG, Sheps, SG, Allen, GL, Joyce, JW. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann Intern Med 1975; 82: 613–8.Google Scholar
Hunder, GG, Bloch, DA, Michel, BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum 1990; 33: 1122–8.Google Scholar
Hutchinson, J. Diseases of the arteries. On a peculiar form of thrombotic arteritis of the aged which is sometimes productive of gangrene. Arch Surg 1890; 1: 323–9.Google Scholar
Hunder, GG. The use and misuse of classification and diagnostic criteria for complex diseases. Ann Intern Med 1998; 129: 417–8.CrossRefGoogle ScholarPubMed
Kermani, TA, Warrington, KJ, Crowson, CS, et al. Large-vessel involvement in giant cell arteritis: A population-based cohort study of the incidence – trends and prognosis. Ann Rheum Dis 2013; 72: 1989–94.CrossRefGoogle ScholarPubMed
Kermani, TA, Schmidt, J, Crowson, CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012; 41: 866–71.Google Scholar
Khan, A, Dasgupta, B. Imaging in giant cell arteritis. Curr Rheumatol Rep 2015; 17: 52, 015–0527-y.Google Scholar
Lariviere, D, Sacre, K, Klein, I, et al. Extra- and intracranial cerebral vasculitis in giant cell arteritis: An observational study. Medicine (Baltimore) 2014; 93: e265.CrossRefGoogle ScholarPubMed
Mahr, AD, Jover, JA, Spiera, RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum 2007; 56: 2789–97.Google Scholar
Ma-Krupa, W, Jeon, MS, Spoerl, S, et al. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med 2004; 199: 173–83.Google Scholar
Mclean, CA, Gonzales, MF, Dowling, JP. Systemic giant cell arteritis and cerebellar infarction. Stroke 1993; 24: 899–902.Google Scholar
Mohammad, AJ, Nilsson, JA, Jacobsson, LT, Merkel, PA, Turesson, C. Incidence and mortality rates of biopsy-proven giant cell arteritis in southern Sweden. Ann Rheum Dis 2015; 74: 993–7.Google Scholar
Mukhtyar, C, Guillevin, L, Cid, MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 2009; 68: 318–23.Google ScholarPubMed
Muratore, F, Pipitone, N, Hunder, GG, Salvarani, C. Discontinuation of therapies in polymyalgia rheumatica and giant cell arteritis. Clin Exp Rheumatol 2013; 31: S86–92.Google ScholarPubMed
Murchison, AP, Gilbert, ME, Bilyk, JR, et al. Validity of the American College of Rheumatology criteria for the diagnosis of giant cell arteritis. Am J Ophthalmol 2012; 154: 722–9.Google Scholar
Nagel, MA, White, T, Khmeleva, N, et al. Analysis of varicella-zoster virus in temporal arteries biopsy positive and negative for giant cell arteritis. JAMA Neurol 2015; 72: 1281–7.CrossRefGoogle ScholarPubMed
Narvaez, J, Bernad, B, Gomez-Vaquero, C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol 2008; 26: S57–62.Google Scholar
Narvaez, J, Bernad, B, Roig-Vilaseca, D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum 2007; 37: 13–9.Google Scholar
Nesher, G, Berkun, Y, Mates, M, et al. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 2004; 50: 1332–7.CrossRefGoogle ScholarPubMed
Parikh, M, Miller, NR, Lee, AG, et al. Prevalence of a normal C-reactive protein with an elevated erythrocyte sedimentation rate in biopsy-proven giant cell arteritis. Ophthalmology 2006; 113: 1842–5.Google Scholar
Pego-Reigosa, R, Garcia-Porrua, C, Pineiro, A, et al. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol 2004; 22: S13–7.Google Scholar
Prieto-Gonzalez, S, Arguis, P, Garcia-Martinez, A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: Prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012; 71: 1170–6.Google Scholar
Salvarani, C, Pipitone, N, Versari, A, Hunder, GG. Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012; 8: 509–21.Google Scholar
Samson, M, Jacquin, A, Audia, S, et al. Stroke associated with giant cell arteritis: A population-based study. J Neurol Neurosurg Psychiatry 2015; 86: 216–21.CrossRefGoogle ScholarPubMed
Save-Soderbergh, J, Malmvall, BE, Andersson, R, Bengtsson, BA. Giant cell arteritis as a cause of death. Report of nine cases. JAMA 1986; 255: 493–6.Google Scholar
Smith, JH, Swanson, JW. Giant cell arteritis. Headache 2014; 54: 1273–89.Google Scholar
Solomon, CG, Weyand, CM, Goronzy, JJ. Giant-cell arteritis and polymyalgia rheumatica. N Engl J Med 2014; 371: 50–7.Google Scholar
Soussan, M, Nicolas, P, Schramm, C, et al. Management of large-vessel vasculitis with FDG-PET: A systematic literature review and meta-analysis. Medicine (Baltimore) 2015; 94: e622.CrossRefGoogle ScholarPubMed
Stacy, RC, Rizzo, JF, Cestari, DM. Subtleties in the histopathology of giant cell arteritis. Semin Ophthalmol 2011; 26: 342–8.Google Scholar
Stone, JH, Tuckwell, K, Dimonaco, S, et al. Trial of tocilizumab in giant-cell arteritis. N Engl J Med 2017; 377: 317–28.Google Scholar
Tomasson, G, Peloquin, C, Mohammad, A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: A cohort study. Ann Intern Med 2014a; 160: 73–80.CrossRefGoogle ScholarPubMed
Tomasson, G, Peloquin, C, Mohammad, A, et al. Risk for cardiovascular disease early and late after a diagnosis of giant-cell arteritis: A cohort study. Ann Intern Med 2014b; 160: 73–80.Google Scholar
Ungprasert, P, Thongprayoon, C, Kittanamongkolchai, W, Srivali, N, Cheungpasitporn, W. Peripheral arterial disease in patients with giant cell arteritis: A meta-analysis. Int J Rheum Dis 2016; 19: 819–25.Google Scholar
Weyand, CM, Hicok, KC, Hunder, GG, Goronzy, JJ. The HLA-DRB1 locus as a genetic component in giant cell arteritis. Mapping of a disease-linked sequence motif to the antigen binding site of the HLA-DR molecule. J Clin Invest 1992; 90: 2355–61.Google Scholar
Weyand, CM, Liao, YJ, Goronzy, JJ. The immunopathology of giant cell arteritis: Diagnostic and therapeutic implications. J Neuroophthalmol 2012; 32: 259–65.Google Scholar
Wilkinson, IM, Russell, RW. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 1972; 27: 378–91.CrossRefGoogle ScholarPubMed
Yates, M, Loke, YK, Watts, RA, MacGregor, AJ. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: Meta-analysis. Clin Rheumatol 2014; 33: 227–36.Google Scholar
Zenone, T. Fever of unknown origin in rheumatic diseases. Infect Dis Clin North Am 2007; 21: 1115, 35, x–xi.CrossRefGoogle ScholarPubMed

Save book to Kindle

To save this book to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Available formats
×

Save book to Dropbox

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Dropbox.

Available formats
×

Save book to Google Drive

To save content items to your account, please confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your account. Find out more about saving content to Google Drive.

Available formats
×